Veracyte, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 219.51M | 296.54M | 361.05M | 445.76M | 517.14M | 16.0% | |
| Cost of Revenue | (74.40M) | (101.58M) | (112.90M) | (147.62M) | (157.10M) | 6.4% | |
Gross Profit | 145.11M | 194.95M | 248.15M | 298.14M | 360.05M | 20.8% | |
| Operating Expenses | |||||||
| Research & Development | (29.84M) | (40.60M) | (57.30M) | (69.29M) | (70.81M) | 2.2% | |
| Selling, General & Administrative | (181.19M) | (174.08M) | (184.23M) | (206.04M) | (210.95M) | 2.4% | |
| General & Administrative | (101.35M) | (76.52M) | (157.63M) | (178.27M) | (110.78M) | -37.9% | |
| Selling & Marketing | (79.84M) | (97.56M) | (26.60M) | (27.77M) | (100.17M) | 260.7% | |
| Depreciation & Amortization | (21.23M) | (29.25M) | (27.19M) | (23.46M) | (21.41M) | -8.7% | |
Operating Income (EBIT) | -81.90M | -41.08M | -85.80M | 16.14M | 74.15M | 359.4% | |
| Non-Operating Items | |||||||
| Interest Income | 135.00K | 1.97M | 7.34M | 11.15M | — | -100.0% | |
| Interest Expense | (241.00K) | (198.00K) | (15.00K) | (2.00K) | — | -100.0% | |
| Other Income/Expenses (Net) | 254.00K | 4.65M | 9.18M | 9.60M | -5.95M | -162.0% | |
Income Before Tax | -81.65M | -36.43M | -76.61M | 25.74M | 68.20M | 164.9% | |
| Income Tax Expense | (6.09M) | (133.00K) | (2.21M) | (1.61M) | (1.85M) | 15.1% | |
Net Income | -75.56M | -36.56M | -74.40M | 24.14M | 66.35M | 174.9% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $-1 | $-1 | $-1 | $0 | $1 | 162.5% | |
| Weighted Avg Shares Outstanding | 67.89M | 71.55M | 72.64M | 76.48M | 78.58M | 2.7% | |
| Weighted Avg Shares Outstanding (Diluted) | 67.89M | 71.55M | 72.64M | 78.16M | 80.57M | 3.1% | |
EBITDA | -60.18M | -6.98M | -49.41M | 49.20M | 89.62M | 82.1% |
Explore VCYT
VCYT in the Healthcare
Mid Cap